Zogenix, Inc. (NASDAQ: ZGNX) has been issued a patent by the U.S. Patent Office for its drug candidate ZX008. The award of this patent, according to the company, marks the first time a patent has been issued covering a fenfluramine treatment of Dravet Syndrome and the seizures associated with it (http://dtn.fm/v69uD). The patent is seen by the company as offering protection of associated claims through 2033.
“This represents the first issued patent covering the treatment of seizures associated with Dravet Syndrome using fenfluramine as an adjunctive therapy, and it is an important milestone for our ZX008 development program,” Stephen J. Farr, Ph.D., president and CEO of Zogenix, added in a news release.
The patent, titled ‘Method for the Treatment of Dravet Syndrome’, was announced by the company on January 30, 2017. Zogenix is currently in a phase 3 program with ZX008 and continues to enroll patients in the U.S. and globally. It has received fast track designation domestically for the treatment of Dravet syndrome, and ZX008 has been defined as an orphan drug in this indication in both the U.S. and Europe.
Zogenix, Inc., is a pharmaceutical company committed to producing commercially-viable central nervous system (CNS) therapies. The company is developing these products for individuals who require innovative treatments to help them with daily functioning.
Farr added that Zogenix is continuing to pursue additional patents related to ZX008 in order to provide additional protection for its lead candidate. The company is also performing more clinical and preclinical work as it seeks to target more intellectual property opportunities, he said.
Zogenix won worldwide patent rights and other intellectual property via its 2014 acquisition of Brabant Pharma Limited, pursuant to a purchase and sales agreement executed with Brabant, the company said.
In its SEC filing of November 8, 2016, Zogenix reported that, in October 2016, it extended through April 2017 its manufacturing services agreement with Pantheon UK Limited. It can be extended again, the company reported. Future purchase minimum obligations totaled $4.6 million at September 30, 2016, through the extension date.
Also on October 2016, Zogenix entered into an asset purchase agreement for $1.5 million to buy the global rights to a preclinical development program for orphan CNS disorders. The company is bound to make future milestone payments over several years, but in the SEC filing Zogenix termed those payments ‘inherently uncertain’ due to the preclinical stage of development.
For more information, visit www.Zogenix.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
